Walvax Biotechnology Co (SZSE:300142) Short-Term Debt & Capital Lease Obligation : ¥356 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Walvax Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥356 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Walvax Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥448 Mil.

Walvax Biotechnology Co Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Walvax Biotechnology Co's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Short-Term Debt & Capital Lease Obligation Chart

Walvax Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

47.59

314.60

120.53

350.93

Walvax Biotechnology Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															75.05	149.53	120.10	350.93	356.43

Walvax Biotechnology Co Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Walvax Biotechnology Co Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Walvax Biotechnology Co (SZSE:300142) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Short-Term Debt & Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106

Website

http://www.walvax.com

Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.

Executives

Wu Yun Yan	Executives
Zhao Jin Long	Executives
Yao Wei	Executives
Zhou Hua	Executives
Shi Jing	Executives
Jiang Run Sheng	Directors, executives
Gong Sun Qing	Executives
	Executives
Yuan Lin	Executives
Fang Guo Liang	Executives
Li Yun Chun	Director
Huang Zhen	Director
Zhang Li	Secretary Dong
Yang Hong Wei	Supervisors
Xu Ke Ren	Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines